China National Accord Medicines (SZSE:200028) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:200028 China National Accord Medicines Corp Ltd SZSE:200028
82 GF Score
Price HK$12.01
GF Value HK$13.65
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is China National Accord Medicines Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

China National Accord Medicines Valuation Rank Related Terms

SZSE:200028
82GF Score
China National Accord Medicines Corp Ltd SZSE:200028
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is China National Accord Medicines (SZSE:200028) Overvalued in 2026?

Based on GuruFocus' analysis, China National Accord Medicines stock appears to be undervalued. The current stock price of HK$12.01 is trading 12% below its estimated GF Value™ of HK$13.65. GuruFocus considers China National Accord Medicines to be Modestly Undervalued.

Key valuation signals for SZSE:200028:

  • Valuation Rank:
  • GF Value™: HK$13.65 vs. price of HK$12.01 (12% below fair value)
  • GF Score™: 82/100 with 6 warning signs

No single metric tells the full story. See the SZSE:200028 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China National Accord Medicines Business Description

Other Exchanges 000028:China
Address No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
82GF Score

Get the complete analysis for SZSE:200028

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$12.01
Price
HK$13.65
GF Value